Skip to main content
SpringerLink
Log in

Research Pipeline III: Biologic Therapies

  • Chapter
  • First Online:
Book cover Advances in Psoriasis

  • 1197 Accesses

Abstract

Psoriasis is a chronic, inflammatory skin condition mediated by activated T-cells. Psoriasis, particularly moderate to severe disease, has a dramatic impact on patient’s quality of life, making effective treatment a priority. Moderate to severe disease often requires systemic therapy. Over the last decade, we have been introduced to several different classes of biologic therapies. The first generation biologics in psoriasis, which are currently widely used, were targeted mostly at tumor necrosis factor alpha (TNF-α). Several new classes of biologic therapy are currently in development. This review will focus on biologic therapies in the pipeline, particularly targeted to treat moderate-to-severe disease. These agents target the IL-12/IL-23 and IL-17 pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Griffiths CE, Clark C, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1–125.

    CAS  PubMed  Google Scholar 

  2. Saudner JN, Mamelak A. Understanding the new clinical landscape for psoriasis: a comparative review of biologics. J Cutan Med Surg. 2004;8:205–12.

    Article  Google Scholar 

  3. Bongartz T, Sutton A, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritisi and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.

    Article  CAS  PubMed  Google Scholar 

  4. D’ Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral mononuclear cells. J Exp Med. 1992;176:1387–98.

    Article  Google Scholar 

  5. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist. 1996;1:88–97.

    CAS  PubMed  Google Scholar 

  6. Hong K, Chu A, Ludvikson BR, et al. IL-12 independently of IFN-gamma plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol. 1999;162:7480–91.

    CAS  PubMed  Google Scholar 

  7. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111:1054–7.

    Article  Google Scholar 

  8. Lee E, Trepicchio W, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122:201–6.

    Article  CAS  PubMed  Google Scholar 

  10. Teunissen MB, Koomen C, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokes production by human keratinocytes. J Invest Dermatol. 1998;111:645–9.

    Article  CAS  PubMed  Google Scholar 

  11. Bartlett BL, Tyring S. Ustekinumab for chronic plaque psoriasis. Lancet. 2008;17:1639–40.

    Article  Google Scholar 

  12. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down regulating type 1 cytokines, chemokines and IL-12/IL-2 in psoriasis. J Immunol. 2006;177:4917–26.

    Article  CAS  PubMed  Google Scholar 

  13. Leonardi C, Kimball A, Papp KA, Yeilding N, Guzzo X, Wang Y, Li S, Dooley LT, Gordon KB. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74.

    Article  CAS  PubMed  Google Scholar 

  14. Papp K, Langley R, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–84.

    Article  CAS  PubMed  Google Scholar 

  15. Griffiths CE, Strober B, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–28.

    Article  CAS  PubMed  Google Scholar 

  16. Gottlieb A, Menter A, Mendelsohn A, Shen Y, Shu L, Guzzo C. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–40.

    Article  CAS  PubMed  Google Scholar 

  17. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013. doi:10.1016/S0140-6736(13)60594-2. pii: S0140-6736(13)60594-2.

  18. Significant improvements in psoriatic arthritis with ustekinumab. http://www.eurekalert.org/pub_releases/2013-06/elar-sii061013.php. Accessed 27 Aug 2013.

  19. Kimball AB, Gordon K, Langley RG, et al. ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled phase 2 trial. Arch Dermatol. 2008;144:200–7.

    Article  CAS  PubMed  Google Scholar 

  20. Gordon K, Langley R, Gottlieb A, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing two dosing regiments of ABT-874 to placebo in patients with moderate to severe psoriasis. J Eur Acad Derm Venereol. 2010;24:1–83.

    Google Scholar 

  21. Menter A, GA, Leonardi C, et al. Efficacy and safety results of ABT-874 vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. J Eur Acad Derm Venereol. 2010;24:1–83.

    Google Scholar 

  22. Strober B, Crowley J, Yamauchi P, et al. ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: efficacy and safety results. J Eur Acad Derm Venereol. 2010;24:1–83.

    Google Scholar 

  23. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, Valdes JM. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365(17):1586–96.

    Article  CAS  PubMed  Google Scholar 

  24. Bangert E, Laimer D, Riedl E, Greisenegger E, Horowitz A, Xu D, et al. Anti-IL-23p19 (MK-3222): effects on the hallmarks of inflammation in psoriasis. J Invest Dermatol. 2012;132:S50–65.

    Article  Google Scholar 

  25. Worcester S. Psoriasis drug MK-3222 progresses through pipeline. In: Rheumatology news digital network. Parsippany, NJ: Frontline Medical Communications; 2013.

    Google Scholar 

  26. Jancin B. Psoriasis drug pipeline extudes progress. In: Rheumatology news. Parsippany, NJ: Frontline Medical Communications; 2013.

    Google Scholar 

  27. Sofen H, Smith S, Matheson R, Leonardi C, Calderon C, Bouman-Thio E, Brodmerkel C, Li K, Merciniak S, Petty K. Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis. Psoriasis: from Gene to Clinic 6th International Congress. Br J Dermatol 2011;165(6):e1–46.

    Article  Google Scholar 

  28. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis and uveitis. Sci Transl Med. 2010;2:1–9.

    Article  Google Scholar 

  29. Papp K, Langley R, Sigureirsson B, Abe M, Baker D, Konno P, Haemmerle S, Thurston H, Papvassilis C, Richards H. Secukinumab in the treatment of moderate to severe plaque psoriasis. Br J Dermatol. 2013;168:412–21.

    Article  CAS  PubMed  Google Scholar 

  30. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–11.

    Article  CAS  PubMed  Google Scholar 

  31. McInnes I, Sieper J, Braun J, Emery P, Heijde D, Isaacs J, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73:349–56.

    Article  CAS  PubMed  Google Scholar 

  32. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62:929–39.

    Article  CAS  PubMed  Google Scholar 

  33. Krueger J, Fretzin S, Suarez-Farinas M, Haslett P, Phipps K, Cameron G, McColm J, Katcherian A, Cueto I, White T. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130:145–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Leonardi C, Matheson R, Zachariae C, Comeron G, Li L, Edson E, Braun D, Banerjee S. A phase 2 trial of LY2439821, an anti-interleukin-17 monoclonal antibody, given subcutaneously in patients with moderate to severe psoriasis. Br J Dermatol. 2011;165:E18–9.

    Google Scholar 

  35. Leonardi C, Matheson R, Zahcariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody Ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–9.

    Article  CAS  PubMed  Google Scholar 

  36. Papp K, Leonardi C, Menter A, Ortonne J, Krueger J, Kricorian G, Ara G, Li J, Russell C, Thompson E, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, NYU Langone Medical School, 240 East 38th Street, New York, NY, 10016, USA

    Arielle R. Nagler MD

  2. Department of Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, Mount Sinai St. Luke’s, 1090 Amsterdam Avenue, Suite 11D, New York, NY, 10025, USA

    Jeffrey M. Weinberg MD

Authors
  1. Arielle R. Nagler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey M. Weinberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey M. Weinberg MD .

Editor information

Editors and Affiliations

  1. St. Luke's -Roosevelt Hospital Center, New York, New York, USA

    Jeffrey M. Weinberg

  2. Department of Dermatology, Icahn School of Medicine, New York, New York, USA

    Mark Lebwohl

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Nagler, A.R., Weinberg, J.M. (2014). Research Pipeline III: Biologic Therapies. In: Weinberg, J., Lebwohl, M. (eds) Advances in Psoriasis. Springer, London. https://doi.org/10.1007/978-1-4471-4432-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4432-8_19

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4431-1

  • Online ISBN: 978-1-4471-4432-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation